Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 502 |
|
|||||
| News | - | ||||||
| Day High | 4.15 | Low High |
|||||
| Day Low | 3.78 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Xenetic Biosciences Inc | XBIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.85 | 18:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.78 | 3.78 | 4.15 | 3.85 | 3.85 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 47 | 502 | - | 2.55 - 5.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 35 | $ 3.78 | USD |
Xenetic Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.93M | 1.54M | - | 2.54M | -4.14M | -2.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Xenetic Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XBIO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.00 | 4.39 | 3.74 | 3.94 | 4,273 | -0.15 | -3.75% |
| 1 Month | 3.96 | 4.74 | 3.74 | 4.31 | 7,413 | -0.11 | -2.78% |
| 3 Months | 3.66 | 4.74 | 3.3301 | 4.15 | 5,903 | 0.19 | 5.19% |
| 6 Months | 3.40 | 4.74 | 2.8696 | 3.85 | 5,259 | 0.45 | 13.24% |
| 1 Year | 4.305 | 5.97 | 2.55 | 3.72 | 14,424 | -0.455 | -10.57% |
| 3 Years | 19.60 | 56.80 | 2.401 | 29.43 | 944,621 | -15.75 | -80.36% |
| 5 Years | 15.40 | 152.50 | 2.401 | 27.29 | 889,417 | -11.55 | -75.00% |
Xenetic Biosciences Description
| Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. |
